C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Piv...(ats HAE attacks at manydifferent areas o...)

Study Design and Key Findings

Findings of I.M.P.A.C.T. 2 were based on treatment with 20 U/kg bodyweight of C1-INH in 355 episodes of HAE attacks at any body location in 39 patients. The main study end-points were: time to onset of symptom relief; complete resolution of all symptoms, and safety.

The median time to the onset of relief was less than 33 minutes for abdominal, facial, laryngeal, and peripheral attacks. The median times to complete resolution of symptoms were less than 2.5 hours for laryngeal attacks, 8 hours for abdominal and 24 hours for facial and peripheral attacks.

No drug-related serious adverse events have been reported to date.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit http://www.cslbehring.com.

Contacts:

Sheila A. Burke, Director, Communications & Public Relations

Worldwide Commercial Operations

CSL Behring

610-878-4209

484-919-2618 (cell)

Sheila.Burke@cslbehring.com

Brian Thompson

MCS

2
'/>"/>